Trial of namilumab for pulmonary sarcoidosis now fully enrolled
The Phase 2 clinical trial RESOLVE-Lung, which is testing namilumab as a treatment for people with chronic pulmonary sarcoidosis, is now fully enrolled. According to Kinevant Sciences, the therapy’s developer, 107 patients with hard-to-treat pulmonary sarcoidosis — disease that’s “not well-controlled despite currently available treatment” — have been…